Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users

NCT01785043 · Completed

Last updated 2026-05-28

This clinical trial compares how two diabetes medications, liraglutide and sitagliptin, affect blood vessel health in adults with type 2 diabetes over a three-month period.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 13 people

Who can join Ages 45–65 · all sexes

Timeline Started 2013-03 · est. completion 2014-09

Where 1 site · Spain

What this study is testing ClinicalTrials.gov NCT01785043 ↗

Description as written by the study sponsor.

Differences in endothelial function amongst Sitagliptin and Liraglutide Users. A randomized, open-label, parallel-group and active controlled trial

Treatments tested

Liraglutide also known as Victoza® Drug

Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
Sitagliptin also known as Januvia Drug

Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.

Main thing measured	Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.
Sponsor	Anna Cruceta
Conditions studied	DIABETES Mellitus Type 2 Not Well Controlled
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01785043 ↗